Overview
Chronic hepatitis E (HEV) is a less commonly recognized but increasingly important condition, particularly among immunocompromised individuals such as transplant recipients. Initially considered an acute self-limiting infection, HEV can persist in certain patient populations, leading to chronic liver inflammation and potential long-term complications. The clinical presentation often overlaps with other liver diseases, making early diagnosis challenging. This guideline aims to provide clinicians with a comprehensive understanding of the clinical features, diagnostic approaches, management strategies, and special considerations for managing chronic HEV, especially in vulnerable groups like transplant recipients.
Clinical Presentation
Chronic HEV infection can manifest with a variety of symptoms, often subtle and nonspecific, making early recognition difficult. A notable case involved a 50-year-old pancreas-kidney transplant recipient who initially presented with undulating fevers and elevated liver function tests (LFTs) following a self-limited acute diarrheal illness [PMID:23564393]. These symptoms, while indicative of systemic inflammation and liver involvement, are not unique to HEV and can mimic other post-transplant complications such as rejection or opportunistic infections. The patient's history of recent gastrointestinal symptoms suggests a possible antecedent acute HEV infection that transitioned into chronicity, highlighting the importance of considering HEV in the differential diagnosis of transplant recipients with unexplained fevers and fluctuating liver enzyme levels. Additional clinical manifestations may include fatigue, malaise, and in some cases, jaundice, though these were not explicitly detailed in the cited case [PMID:23564393].
In clinical practice, the insidious onset and variability of symptoms necessitate a high index of suspicion, particularly in immunocompromised individuals. Monitoring for subtle changes in liver enzymes and unexplained systemic symptoms is crucial for early detection. The variability in presentation underscores the need for thorough patient history taking, including recent travel or exposure risks, and a comprehensive physical examination to guide further diagnostic testing.
Diagnosis
Diagnosing chronic HEV infection requires a multifaceted approach due to its nonspecific clinical presentation. The case study mentioned a comprehensive evaluation that initially failed to pinpoint the cause, emphasizing the diagnostic challenges [PMID:23564393]. Definitive diagnosis typically relies on laboratory confirmation through serology and molecular testing. Serological assays can detect HEV-specific antibodies, which are useful for identifying past or current infection, but they may not distinguish between acute and chronic phases without additional context [PMID:23564393]. More definitive evidence comes from detecting HEV RNA through polymerase chain reaction (PCR) in serum or stool samples, as was done in the cited case where positive results from both sources confirmed the diagnosis [PMID:23564393].
In clinical practice, clinicians should consider ordering both serological tests and PCR for HEV RNA, especially in immunocompromised patients with persistent liver enzyme elevations or unexplained systemic symptoms. The involvement of specialized laboratories, such as the CDC in the referenced case, may be necessary for accurate and sensitive testing, particularly when initial evaluations are inconclusive. Early and accurate diagnosis is critical for timely intervention and preventing potential long-term liver damage.
Management
The management of chronic HEV infection primarily focuses on antiviral therapy, with ribavirin emerging as a cornerstone treatment based on the case study provided [PMID:23564393]. In the described patient, ribavirin therapy led to significant clinical improvement, characterized by normalization of transaminase activities and resolution of fever within a month, with undetectable HEV PCR levels at follow-up assessments at 6 and 10 months [PMID:23564393]. This outcome underscores the efficacy of ribavirin in managing chronic HEV, particularly in immunocompromised hosts where spontaneous resolution is less likely.
However, the optimal duration of treatment and potential need for combination therapy (e.g., with interferon) remain areas of ongoing research and clinical exploration. For transplant recipients and other immunosuppressed patients, careful monitoring of liver function and viral load is essential during treatment to adjust therapy as needed. Additionally, managing underlying immunosuppression may be necessary to enhance treatment efficacy and prevent recurrent infection. Close collaboration with infectious disease specialists and hepatologists is recommended to tailor treatment plans to individual patient needs, considering factors such as transplant status, concurrent medications, and overall health condition.
Special Populations
Chronic HEV infection poses significant risks in special populations, particularly those with compromised immune systems, such as organ transplant recipients and patients with chronic allograft rejection. The case study highlights the heightened vulnerability of these individuals, where the immune system's reduced capacity to clear the virus can lead to persistent infection [PMID:23564393]. Immunosuppressive therapies used to prevent graft rejection further complicate the clinical picture by potentially exacerbating viral persistence and liver inflammation.
In clinical practice, transplant centers should maintain heightened vigilance for HEV in their patient populations, integrating routine screening protocols for HEV antibodies and RNA in those with unexplained liver enzyme elevations or systemic symptoms. Early identification and intervention are crucial to mitigate the risk of chronic liver disease progression and potential graft dysfunction. Tailored monitoring strategies, including frequent liver function tests and viral load assessments, are essential for these high-risk groups to ensure timely therapeutic adjustments and prevent severe complications.
Key Recommendations
These recommendations are based on expert clinical experience and the evidence provided by specific case studies, emphasizing the importance of proactive and multidisciplinary approaches in managing chronic HEV, particularly in vulnerable patient groups.
References
1 Im GY, Sehgal V, Ward SC. A case of undulating fevers and elevated liver tests after pancreas-kidney transplantation. Seminars in liver disease 2013. link
1 papers cited of 5 indexed.